Temozolomide is an alkylating chemotherapeutic agent used in malignant neuroendocrine neoplasia, melanoma, brain metastases and an essential component of adjuvant therapy in the treatment of glioblastoma multiforme and anaplastic astrocytoma. Since 2006, it has been used for the treatment of pituitary carcinomas and aggressive pituitary adenomas. Here, we discuss the current indications and results of temozolomide therapy in pituitary tumors, as well as frequently asked questions regarding temozolomide treatment, duration of therapy, dosage, tumor recurrence and resistance.
CITATION STYLE
Syro, L. V., Rotondo, F., Ortiz, L. D., & Kovacs, K. (2018, August 1). Treatment of pituitary tumors with temozolomide: An update. Endocrine-Related Cancer. BioScientifica Ltd. https://doi.org/10.1530/ERC-18-0015
Mendeley helps you to discover research relevant for your work.